TLDR Telix H1 revenue rises 22% to $477M as adjusted EBITDA jumps 146% year over year. Precision Medicine revenue climbs 27% as Illuccix and Gozellix drive higher sales. Telix invests $124M in R&D while advancing prostate, kidney and brain programs. Manufacturing revenue reaches ...